American Friends of Tel Aviv University
http://www.eurekalert.org/pub_releases/2012-05/afot-fpi050212.php
Freezing Parkinson's in its tracks
Tel Aviv University researcher developing therapy to halt symptoms in Parkinson's patients
Parkinson's disease, a disorder which affects movement and cognition, affects over a million Americans, including actor Michael J. Fox, who first brought it to the attention of many TV-watching Americans. It's characterized by a gradual loss of neurons that produce dopamine. Mutations in the gene known as DJ-1 lead to accelerated loss of dopaminergic neurons and result in the onset of Parkinson's symptoms at a young age.The ability to modify the activity of DJ-1 could change the progress of the disease, says Dr. Nirit Lev, a researcher at Tel Aviv University's Sackler Faculty of Medicine and a movement disorders specialist at Rabin Medical Center. Working in collaboration with Profs. Dani Offen and Eldad Melamed, Dr. Lev has now developed a peptide which mimics DJ-1's normal function, thereby protecting dopamine- producing neurons. What's more, the peptide can be easily delivered by daily injections or absorbed into the skin through an adhesive patch.Based on a short protein derived from DJ-1 itself, the peptide has been shown to freeze neurodegeneration in its tracks, reducing problems with mobility and leading to greater protection of neurons and higher dopamine levels in the brain. Dr. Lev says that this method, which has been published in a number of journals including the Journal of Neural Transmission, could be developed as a preventative therapy.
Guarding dopamine levels
As we age, we naturally lose dopamine-producing neurons. Parkinson's patients experience a rapid loss of these neurons from the onset of the disease, leading to much more drastic deficiencies in dopamine than the average person. Preserving dopamine-producing neurons can mean the difference between living life as a Parkinson's patient or aging normally, says Dr. Lev.
The researchers set out to develop a therapy based on the protective effects of DJ-1, using a short peptide based on the healthy version of DJ-1 itself as a vehicle. "We attached the DJ-1-related peptide to another peptide that would allow it to enter the cells, and be carried to the brain," explains Dr. Lev.
In pre-clinical trials, the treatment was tested on mice utilizing well-established toxic and genetic models for Parkinson's disease. From both a behavioral and biochemical standpoint, the mice that received the peptide treatment showed remarkable improvement. Symptoms such as mobility dysfunctions were reduced significantly, and researchers noted the preservation of dopamine-producing neurons and higher dopamine levels in the brain.
Preliminary tests indicate that the peptide is a viable treatment option. Though many peptides have a short life span and degrade quickly, this peptide does not. Additionally, it provides a safe treatment option because peptides are organic to the body itself.
Filling an urgent need
According to Dr. Lev, this peptide could fill a gap in the treatment of Parkinson's disease. "Current treatments are lacking because they can only address symptoms there is nothing that can change or halt the disease," she says. "Until now, we have lacked tools for neuroprotection."
The researchers also note the potential for the peptides to be used preventatively. In some cases, Parkinson's can be diagnosed before motor symptoms begin with the help of brain scans, explains Dr. Lev, and patients who have a genetic link to the disease might opt for early testing. A preventative therapy could help many potential Parkinson's patients live a normal life.
###
American Friends of Tel Aviv University (www.aftau.org)
supports Israel's leading, most comprehensive and most sought-after
center of higher learning. Independently ranked 94th among the world's
top universities for the impact of its research, TAU's innovations and
discoveries are cited more often by the global scientific community than
all but 10 other universities.
Internationally recognized for the scope and groundbreaking nature of its research and scholarship, Tel Aviv University consistently produces work with profound implications for the future.
___________________________
Internationally recognized for the scope and groundbreaking nature of its research and scholarship, Tel Aviv University consistently produces work with profound implications for the future.
___________________________
http://israel21c.org/environment/the-super-israeli-superabsorbent/?utm_sourc
e=Newsletter+5%2F2%2F2012&utm_campaign=May+2+2012+&utm_medium=email
e=Newsletter+5%2F2%2F2012&utm_campaign=May+2+2012+&utm_medium=email
The super Israeli superabsorbent
Companies on three continents are taking note of a safe, biodegradable Israeli material for everything from diapers to diet pills.
Companies on three continents are taking note of a safe, biodegradable Israeli material for everything from diapers to diet pills.
By Abigail Klein Leichman May 2, 2012,
How can one product help people lose weight safely, grow crops with less water and dispose of diapers without harming the earth?
How can one product help people lose weight safely, grow crops with less water and dispose of diapers without harming the earth?
Two years ago, ISRAEL21c reported on an all-natural superabsorbent polymer (SAP) invented in Israel that can do all this and more.
Until our story appeared, the maker of this novel material, the Kiryat Gat-based Exotech Bio Solutions,
had been unable to raise enough capital to make sufficient SAP for
interested manufacturers.“We needed help being discovered,” co-CEO Mendy
Axlerad tells ISRAEL21c.
As a result of our article, entrepreneurs
in Europe and South America contacted Exotech and now are building
factories to produce the unique Israeli product.
“A company from northern Portugal contacted us asking for a
sample, and after we sent it, they said, ‘If you had a partner, would
you build a factory?’ They came to visit us and we signed an agreement to build the first factory in the world to produce our SAP,” says Axlerad, who sees this as a stepping stone to all of environmentally conscious Europe.
“We expect to start production in seven to nine months from now, making 5,000 tons per year.”
And that’s not all. About half a year after that, a new German
facility will start producing Exotech’s SAP and transfer it via pipeline
to a new diaper factory next door. “Nothing like this exists anywhere
else,” says Axlerad. “The raw material will move in a fully ecological
way to produce the finished product.”
He adds that Exotech is selling only the rights to use the
material. “It remains an Israeli technology. For me, this is important
from a business and personal point of view.”
Bye-bye to petroleum-based products
Most super-absorbent materials are acrylic byproducts of oil, Axlerad explains. “This presents many disadvantages, from high costs to environmental harm. We developed a new way to make superabsorbents from natural materials and chemicals, using a technology based on water.”
Exotech’s SAP swells when wet and forms a gel to trap fluid. Unaffected by the fluctuations of oil prices, this technology is considerably cheaper,takes less energy to produce and results in a fully biodegradable material with many potential applications.
“We have a client in the United States looking to buy the product and start producing biodegradable diapers
in small quantities to test out the market,” relates Axlerad. “They
have good contacts with other US market suppliers. For us, this is very
big progress.”
There is also news in SAP’s potential for farming. Exotech just signed an agreement with a South American company to develop the product into absorbent underground reservoirs for crops.
“One of the bigger problems with watering is that you don’t know
when you’ll have enough rainfall,” Axlerad says. “So you must irrigate,
but plants do not retain water in a consistent way. Our material permits
a new concept in irrigation to manage the water when you have too much and release water when you have too little. The plants make their decision to take water from the reservoir created with our material, depending on their needs.”
Israel’s Volcani Institute-Agricultural Research Organization found this product reduces water consumption by 60-80 percent, “which is of interest not only in Israel but all over the world,” Axlerad points out.
An added benefit is that the SAP material degrades at the end of the season into ammonia, a natural fertilizer.
A European university recently released results of its study on the
material, showing the Israeli SAP meets European Union standards for
biodegradability, with no toxic residuals.
No need to forgo that cookie
Several years ago, the six-employee Exotech partnered with
Boston-based PureTech Ventures to form Gelesis, a corporation that
developed a pill to treat obesity using the SAP. The pill expands in the stomach, causing a feeling of fullness, and is eliminated after several hours.
“Now they are working to get financing,”
Axlerad says. “We tested the pill in vitro, in vivo and then in small
animals and big animals, and all results were positive. We finished the
protocols to start clinical studies in human beings, which is a little
complicated and very expensive. I am feeling very positive about
obtaining enough financing to start the project.”
This market is worth billions, considering that in United States, 30 percent of the population is considered obese.
Meanwhile, Exotech
Israel is developing SAP as a food additive to give the body-conscious
age group from 15 to 25 the ability to eatcommercially baked goodies
without gaining pounds. Putting a bit of the plant-based SAP
in the standard recipe means that when it mixes with liquids in the
stomach, one serving expands in volume four or five times over.
“I presented this idea to a big producer of biscuits and cookies overseas, and they were very excited,”
says Axlerad. “It’s a green card to the world of dietary pleasure. It’s
a way down the road, but not as long as a medical device because it’s
not a pharmaceutical; it’s food.”
The company is open to investors but mainly seeks collaborators. “If someone can give us new horizons, we are ready to talk,” says Axlerad.
No comments:
Post a Comment